| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 93.94 | 7.5% |
| Total Income | 93.94 | 7.5% |
| Expenditure | 105.26 | 1.5% |
| PBT | -21.21 | 536.9% |
| Net Profit | -21.68 | 448.9% |
| OPM | -12.04% | 9.93pp |
| NPM | -23.08% | 19.18pp |
| EPS | -0.18 | 350.0% |
Accuray Reports Q1 FY26 Revenue of $93.9 Million
04 May 2026 · 4 May, 8:06 am
Summary
Accuray Incorporated reported a decrease in total net revenue for the first quarter of fiscal 2026, with $93.9 million compared to $101.5 million in the prior year. Product revenue saw a significant decrease, while service revenue increased. The company experienced a net loss of $21.7 million, a substantial increase from the $4.0 million loss in the same quarter of the previous year. Accuray is reaffirming its fiscal year 2026 guidance, expecting total net revenue in the range of $471 million to $485 million and adjusted EBITDA in the range of $31 million to $35 million.
Key Highlights
- 1
Accuray reported total net revenue of $93.9 million in the first quarter of fiscal 2026, a decrease of 7 percent compared to the prior fiscal year first quarter.
- 2
Product revenue decreased by 23 percent to $37.2 million in the first quarter of fiscal 2026.
- 3
Service revenue increased by 7 percent to $56.8 million in the first quarter of fiscal 2026.
- 4
The company's gross profit was $26.5 million, representing 28.3 percent of total net revenue, compared to $34.5 million, or 33.9 percent, in the prior fiscal year first quarter.
- 5
Net loss was $21.7 million, or $0.18 per share, in the first quarter of fiscal 2026, compared to a net loss of $4.0 million, or $0.04 per share, in the prior fiscal year first quarter.
- 6
Gross product orders were $39.6 million in the first quarter of fiscal 2026, compared to $55.4 million in the prior fiscal year first quarter.
- 7
Order backlog as of September 30, 2025, was $395.7 million, approximately 16 percent lower than at the end of the prior fiscal year first quarter.
Management Comments
Steve La Neve
As the new CEO of Accuray, I have a tremendous amount of respect for what our radiotherapy systems can do to improve cancer patients’ lives for the better. While our first quarter results were soft, we were pleased to see continued expansion of our CyberKnife® and Radixact® Systems into new hospitals and markets, and we are excited about the introduction of Accuray Stellar and its potential in the U.S., where it is currently available for sale.
Informational and educational content only. Not investment advice.